Lung cancer in general, and non-small cell lung cancer (NSCLC) in particular, is often asymptomatic in the early stages of the disease. When symptoms do occur in an early stage (e.g., endobronchial ...

Scientists have developed a new method for accurately predicting gene changes that cause lung cancer, without the need for ...

Patients with Stage I disease have a 2-year overall survival (OS) of 90-97% and a 5-year OS of 77-92%. Patients with Stage II cancer show a 2-year OS of 72-87% and a 5-year OS of 53-68%. With Stage ...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Strata Oncology, Inc. (“Strata”), a next-generation precision oncology company enabling smarter cancer treatment, today announced that it will present new data in ...

Perception and awareness of cancer immunotherapy among healthcare professionals and students at a tertiary referral center in the MENA region. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, ...

Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for which ...

Lung cancer remains the leading cause of cancer deaths in the United States and older adults are at higher risk. But only ...

Lung transplant for stage IV lung cancer achieved 100% one-year survival in 17 NSCLC patients in a landmark JAMA study from ...

LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S.